These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25777682)

  • 1. Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.
    Seah JA; Leibowitz-Amit R; Atenafu EG; Alimohamed N; Knox JJ; Joshua AM; Sridhar SS
    Clin Genitourin Cancer; 2015 Aug; 13(4):e229-e233. PubMed ID: 25777682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer.
    Buisan O; Orsola A; Areal J; Font A; Oliveira M; Martinez R; Ibarz L
    Clin Genitourin Cancer; 2017 Feb; 15(1):145-151.e2. PubMed ID: 27364982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
    Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
    Black AJ; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand S; Sridhar SS; Black PC
    Urol Oncol; 2020 Jan; 38(1):3.e17-3.e27. PubMed ID: 31676278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.
    Buisan O; Orsola A; Oliveira M; Martinez R; Etxaniz O; Areal J; Ibarz L
    Clin Genitourin Cancer; 2017 Aug; 15(4):e697-e706. PubMed ID: 28274590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.
    Viers BR; Boorjian SA; Frank I; Tarrell RF; Thapa P; Karnes RJ; Thompson RH; Tollefson MK
    Eur Urol; 2014 Dec; 66(6):1157-64. PubMed ID: 24630414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder.
    Potretzke A; Hillman L; Wong K; Shi F; Brower R; Mai S; Cetnar JP; Abel EJ; Downs TM
    Urol Oncol; 2014 Jul; 32(5):631-6. PubMed ID: 24629498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of preoperative butyrylcholinesterase as an independent predictor of survival in patients with muscle-invasive bladder cancer treated with radical cystectomy.
    Koie T; Ohyama C; Yamamoto H; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Kitayam M; Hirota K
    Urol Oncol; 2014 Aug; 32(6):820-5. PubMed ID: 24951323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Muscle Invasive Bladder Cancer Treated With Neoadjuvant Chemotherapy and Radical Cystectomy.
    von Deimling M; Schuettfort VM; D'Andrea D; Pradere B; Grossmann NC; Kawada T; Yanagisawa T; Majdoub M; Laukhtina E; Rajwa P; Quhal F; Mostafaei H; Fajkovic H; Teoh JY; Moschini M; Karakiewicz PI; Fisch M; Rink M; Shariat SF
    Clin Genitourin Cancer; 2023 Aug; 21(4):430-441. PubMed ID: 36781346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of perioperative lymphocyte-monocyte ratio in patients with bladder cancer undergoing radical cystectomy.
    Yoshida T; Kinoshita H; Yoshida K; Mishima T; Yanishi M; Inui H; Komai Y; Sugi M; Inoue T; Murota T; Fukui K; Harada J; Kawa G; Matsuda T
    Tumour Biol; 2016 Aug; 37(8):10067-74. PubMed ID: 26819209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy.
    Morizawa Y; Miyake M; Shimada K; Hori S; Tatsumi Y; Nakai Y; Anai S; Tanaka N; Konishi N; Fujimoto K
    Urol Oncol; 2016 Jun; 34(6):257.e11-7. PubMed ID: 27038696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
    Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
    Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer.
    Mendoza-Valderrey A; Choe J; Kessler DM; Jimenez G; Li X; Kolker S; Allen W; Linehan JA; Twardowski PW; Ascierto ML
    Cancer Med; 2024 Aug; 13(15):e70088. PubMed ID: 39119802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia as a Predictive Factor for Response to Upfront Cisplatin-Based Chemotherapy in Patients with Muscle-Invasive Urothelial Bladder Cancer.
    ; Mari A; D'Andrea D; Kimura S; Resch I; Shariat SF; Klatte T
    Urol Int; 2018; 101(2):197-200. PubMed ID: 30089304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the Preoperative Neutrophil-to-Lymphocyte Ratio Significantly Predict the Conditional Survival Probability in Muscle-invasive Bladder Cancer Patients Undergoing Radical Cystectomy?
    Kang M; Balpukov UJ; Jeong CW; Kwak C; Kim HH; Ku JH
    Clin Genitourin Cancer; 2017 Jun; 15(3):e411-e420. PubMed ID: 28162942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.